Compare CAR & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CAR | NAMS |
|---|---|---|
| Founded | 1946 | 2019 |
| Country | United States | Netherlands |
| Employees | N/A | 100 |
| Industry | Rental/Leasing Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.5B |
| IPO Year | 1998 | N/A |
| Metric | CAR | NAMS |
|---|---|---|
| Price | $370.59 | $36.27 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 8 |
| Target Price | ★ $127.57 | $46.75 |
| AVG Volume (30 Days) | ★ 2.1M | 793.0K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 50.71 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $11,652,000,000.00 | N/A |
| Revenue This Year | $2.17 | $17.96 |
| Revenue Next Year | $1.78 | $540.65 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $66.79 | $15.70 |
| 52 Week High | $307.97 | $42.00 |
| Indicator | CAR | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 94.42 | 65.66 |
| Support Level | $126.54 | $34.05 |
| Resistance Level | N/A | $37.43 |
| Average True Range (ATR) | 32.07 | 1.71 |
| MACD | 21.57 | 0.62 |
| Stochastic Oscillator | 98.13 | 97.91 |
Avis Budget Group Inc is a provider of mobility solutions through its three brands Avis, Budget and Zipcar, as well as several other brands, well recognized in their respective markets. Its brands offer a range of options, from car and truck rental to car sharing. The company operates in two reportable business segments: Americas - (i) vehicle rental operations in North America, South America, Central America and the Caribbean, (ii) car sharing operations in certain of these markets, and (iii) licensees in the areas in which do not operate directly. International - consisting of (i) vehicle rental operations in Europe, the Middle East, Africa, Asia and Australasia, (ii) car sharing operations in certain of these markets, and (iii) licensees in the areas in which do not operate directly.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.